Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Fumiyuki Yamasaki(Hiroshima University), Naoto T. Ueno(Breast Cancer Care)
Cited by 81
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
|Molecular Endocrinology|2010|232